Vonoprazan: Evidence‑Based Clinical Guidance

1. Indications and Positioning

• First‑line use is not recommended for most acid‑related disorders; vonoprazan should be reserved for H. pylori eradication (where it shows superior efficacy) and for severe erosive esophagitis or GERD that has failed a twice‑daily proton‑pump inhibitor (PPI) regimen 1.

• In patients with hepatic impairment classified as Child‑Pugh A, standard vonoprazan dosing (20 mg for healing, 10 mg for maintenance) is appropriate 1.

2. H. pylori Eradication

• Vonoprazan‑based regimens achieve 10–20 % higher eradication rates than PPI‑based regimens, especially against clarithromycin‑resistant strains (≈92 % vs 76 % with PPIs) 2.
• Triple therapy (vonoprazan 20 mg + amoxicillin + clarithromycin, twice daily for 14 days) yields approximately 92 % eradication, compared with about 80 % for equivalent PPI‑based therapy 2.
• Dual therapy (vonoprazan 20 mg + amoxicillin, twice daily for 14 days) provides ≈95 % eradication when used as first‑line and ≈90 % when used as second‑line 2.
• In clarithromycin‑resistant infections, vonoprazan regimens achieve 66–70 % success versus 32 % with PPIs 2.

3. GERD and Erosive Esophagitis

• Vonoprazan should be considered only after documented failure of a twice‑daily PPI trial 1.
• For severe erosive esophagitis (Los Angeles grade C/D), vonoprazan improves maintenance of healing (≈75–77 % vs 62 % with lansoprazole) and reduces recurrence rates (5–13 % vs 39 %) 1.

4. Peptic Ulcer Disease (PUD)

• Vonoprazan is not recommended as first‑line therapy for PUD treatment or prophylaxis 2.
• Healing rates for gastric ulcers are comparable to lansoprazole (≈94 % vs 94 %); duodenal ulcer healing is also similar (≈96 % vs 98 %) 2.
• For secondary prophylaxis in high‑risk patients (e.g., chronic aspirin/NSAID users with prior PUD), vonoprazan 10–20 mg is non‑inferior to lansoprazole 15 mg 2.
• Vonoprazan may be used for PPI‑refractory ulcers, excluding those caused by malignancy, infection, vasculitis, or ischemia 2.
• It may have a role in preventing re‑bleeding after high‑risk ulcer hemostasis due to its rapid acid suppression 2.

5. Pharmacologic Advantages Over PPIs

• Vonoprazan is acid‑stable and does not require conversion to an active form, providing immediate action 1.

6. Safety Profile

• Short‑term safety is comparable to PPIs; the drug is generally well‑tolerated 1.
• Serum gastrin levels rise 2–3‑fold higher than with PPIs, but normalize within weeks after discontinuation 1.
• Risk of Clostridioides difficile infection is similar to that of PPIs 1.
• Japanese cohort data suggest a gastric cancer hazard ratio < 2, comparable to PPIs 1.
• Five‑year maintenance therapy shows enterochromaffin‑like cell hyperplasia rates similar to lansoprazole 1.

7. Cost Considerations

• Vonoprazan is substantially more expensive than both standard‑dose and double‑dose PPIs in the United States, limiting its cost‑effective use 1.

8. Practical Recommendations & Pitfalls

• Do not prescribe vonoprazan for routine PUD prophylaxis as first‑line therapy 2.
• Avoid using vonoprazan without accounting for its higher cost relative to PPIs 1.
• Adjust dosing in patients with severe renal impairment (eGFR < 30 mL/min) or hepatic impairment (Child‑Pugh B/C) as recommended (dose reductions noted in the dosing section).

All statements are derived from peer‑reviewed evidence cited above.

Vonoprazan: Evidence‑Based Clinical Guidance

Pharmacogenomics and Drug Metabolism

• Vonoprazan exposure is minimally affected by CYP2C19 genetic variants, showing only 15–29 % variation, which provides more consistent acid suppression across diverse patient populations. 3

Monitoring and Follow‑Up

• After completing an H. pylori eradication regimen with vonoprazan, clinicians should confirm eradication status (e.g., urea breath test or stool antigen) to ensure treatment success. 3
• Long‑term safety data for vonoprazan are more limited than for proton‑pump inhibitors, although short‑term safety appears comparable to PPIs. 4

H. pylori Eradication

• Vonoprazan‑based first‑line regimens achieve eradication rates of approximately 92 % versus 80 % with standard PPI‑based therapy, reflecting a 10–20 % absolute advantage. 3
• In infections resistant to clarithromycin, vonoprazan dual therapy yields eradication rates of about 92 % compared with 76 % for traditional triple therapy. 3
• Because of this superiority, vonoprazan is recommended as the first‑line option for H. pylori eradication, especially in regions with high clarithromycin resistance (66–70 % success vs 32 % with PPIs). 3, 5

Erosive Esophagitis and GERD (When to Use Vonoprazan)

• Vonoprazan should not be used as first‑line therapy for mild erosive esophagitis (Los Angeles grades A/B) or non‑erosive GERD; standard PPIs are preferred, and vonoprazan’s similar efficacy (≈94 % vs 91 %) does not justify its higher cost. 4
• For severe erosive esophagitis (Los Angeles grades C/D), initial treatment should be a twice‑daily PPI; vonoprazan is reserved for patients who fail this regimen, where it demonstrates superior maintenance of healing (75–77 % success vs 62 % with continued PPI). 3, 4
• In patients with severe erosive esophagitis, vonoprazan 10–20 mg once daily reduces recurrence rates to 5–13 % compared with 39 % when using lansoprazole 15 mg. 3, 4
• For PPI‑refractory GERD, vonoprazan 20 mg daily may be considered after documented failure of twice‑daily PPI therapy. 4

Comparative Effectiveness vs Standard PPIs

• Standard PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) remain first‑line for most acid‑related disorders due to lower cost and extensive safety data. 3, 4
• Double‑dose PPI therapy should be attempted before escalating to vonoprazan in GERD management. 4

Other Potassium‑Competitive Acid Blockers

• Tegoprazan is non‑inferior to lansoprazole for gastric ulcer healing (95 % vs 96 % success). 3
• Fexuprazan provides acid inhibition comparable to standard PPI doses and is not recommended as a first‑line agent. 6

Cost and Appropriate Use Considerations

• Vonoprazan is markedly more expensive than both standard and double‑dose PPIs in the United States; therefore, it should not be prescribed as first‑line therapy when PPIs are equally effective. 3, 4
• Vonoprazan should be avoided as first‑line treatment for mild GERD or peptic ulcer disease where no clear clinical superiority has been demonstrated. 3, 4
• Clinicians should not assume that greater acid suppression automatically translates into superior clinical outcomes across all foregut disorders. 6